Description

Insulin Icodec Injection (Awiqli) is a novel once-weekly basal insulin analog developed by Novo Nordisk A/S. Supplied as a 700 units/mL formulation in a 1 mL prefilled pen (without needle), this preparation is designed to support advanced laboratory studies in the field of endocrinology, metabolic disease, and insulin pharmacodynamics.

Insulin Icodec (Awiqli) is under investigation globally for its ability to maintain glucose stability over long periods, enabling fewer dosing interventions in Type 2 Diabetes models. This makes it a valuable compound in research involving insulin resistance, GLUT4 regulation, pancreatic beta-cell function, and long-acting insulin kinetics.

?? For Laboratory Use Only – Not for human or animal administration.

Specifications Table

Research Applications

• Long-acting insulin analog modeling

• Pharmacokinetic studies in diabetic models

• Receptor binding and glucose uptake assays

• Weekly dosing compliance simulations

• Insulin metabolism in cell or animal models

Disclaimer

This product is intended for experimental laboratory use only. Not approved for medical, veterinary, or human application. Researchers must follow proper handling protocols and local regulations.